Based on the key indicators related to Arcus Biosciences' liquidity, profitability, solvency, and operating efficiencyBased on the analysis of, Arcus Biosciences is not in a good financial situation at this time. It has a very high odds of going through financial crisis in January. At this time, Arcus Biosciences' Property Plant Equipment is comparatively stable compared to the past year. Net Invested Capital is likely to gain to about 473.8 M in 2024, whereas Total Current Liabilities is likely to drop slightly above 99.4 M in 2024. Key indicators impacting Arcus Biosciences' financial strength include:
The essential information of the day-to-day investment outlook for Arcus Biosciences includes many different criteria found on its balance sheet. An individual investor should monitor Arcus Biosciences' cash flow, debt, and profitability to accurately make informed decisions on whether to invest in Arcus Biosciences.
Please note, the imprecision that can be found in Arcus Biosciences' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Arcus Biosciences. Check Arcus Biosciences' Beneish M Score to see the likelihood of Arcus Biosciences' management manipulating its earnings.
Arcus Biosciences Stock Summary
Arcus Biosciences competes with Cullinan Oncology, Annexon, Structure Therapeutics, Relay Therapeutics, and Day One. Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company was incorporated in 2015 and is headquartered in Hayward, California. Arcus Biosciences operates under Biotechnology classification in the United States and is traded on New York Stock Exchange. It employs 366 people.
Specialization
Health Care, Pharmaceuticals, Biotechnology & Life Sciences
The reason investors look at the income statement is to determine what Arcus Biosciences' earnings per share (EPS) will be in order to see if they want to buy more shares or not. For example, if a company earned $20 million in the last quarter and has 100,000 shares outstanding, its EPS is 20 cents. If you find that this number beats analysts' forecasts or is higher than it was from the same period last year, then you might want to buy more of this stock even though its price per share may not have changed.
Comparative valuation techniques use various fundamental indicators to help in determining Arcus Biosciences's current stock value. Our valuation model uses many indicators to compare Arcus Biosciences value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Arcus Biosciences competition to find correlations between indicators driving Arcus Biosciences's intrinsic value. More Info.
Arcus Biosciences is rated below average in return on equity category among its peers. It is rated below average in return on asset category among its peers . At this time, Arcus Biosciences' Return On Equity is comparatively stable compared to the past year. Comparative valuation analysis is a catch-all technique that is used if you cannot value Arcus Biosciences by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.
Arcus Biosciences Systematic Risk
Arcus Biosciences' systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Arcus Biosciences volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was twenty-eight with a total number of output elements of thirty-three. The Beta measures systematic risk based on how returns on Arcus Biosciences correlated with the market. If Beta is less than 0 Arcus Biosciences generally moves in the opposite direction as compared to the market. If Arcus Biosciences Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Arcus Biosciences is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Arcus Biosciences is generally in the same direction as the market. If Beta > 1 Arcus Biosciences moves generally in the same direction as, but more than the movement of the benchmark.
Today, most investors in Arcus Biosciences Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Arcus Biosciences' growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of Arcus Biosciences growth as a starting point in their analysis.
Arcus Biosciences December 3, 2024 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Arcus Biosciences help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Arcus Biosciences. We use our internally-developed statistical techniques to arrive at the intrinsic value of Arcus Biosciences based on widely used predictive technical indicators. In general, we focus on analyzing Arcus Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Arcus Biosciences's daily price indicators and compare them against related drivers.
When running Arcus Biosciences' price analysis, check to measure Arcus Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Arcus Biosciences is operating at the current time. Most of Arcus Biosciences' value examination focuses on studying past and present price action to predict the probability of Arcus Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Arcus Biosciences' price. Additionally, you may evaluate how the addition of Arcus Biosciences to your portfolios can decrease your overall portfolio volatility.